Catalina Capital Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-4,264
Closed -$367K 309
2024
Q4
$367K Buy
4,264
+634
+17% +$68.6K 0.12% 171
2024
Q3
$432K Sell
3,630
-1
-0% -$133 0.14% 143
2024
Q2
$518K Buy
3,631
+19
+0.5% +$2.52K 0.19% 113
2024
Q1
$464K Buy
+3,612
New +$430K 0.19% 112

Other funds holding NVO

Catalina Capital Group's NVO Position: Q1 2025 in Review

Catalina Capital Group sold out of Novo Nordisk (NVO) in Q1 2025, closing a stake of 4,264 shares — an estimated $367K sold.

Catalina Capital Group first reported a position in NVO in Q1 2024 and held it in 4 quarters. The position peaked at $518K in Q2 2024. 1,528 funds tracked by Wall St. Rank hold NVO as of Q1 2025.

  • Catalina Capital Group reported no remaining Novo Nordisk position as of Q1 2025 after selling out during the quarter.
  • Catalina Capital Group sold 4,264 Novo Nordisk shares in Q1 2025, an estimated $367K.
  • Catalina Capital Group first reported a position in Novo Nordisk in Q1 2024 and held it in 4 quarters.
  • Catalina Capital Group's Novo Nordisk position peaked at $518K in Q2 2024.
  • 1,528 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2025.

Based on Catalina Capital Group's 13F filing for Q1 2025, filed 21 Apr 2025.